01:17 PM EST, 01/17/2025 (MT Newswires) -- Boston Scientific ( BSX ) is on track to be the highest performing large cap medtech company, RBC Capital Markets said in a note emailed Friday.

The firm said it had come away more bullish on the company's 2025 setup after catching up with the company and its investors.

The firm cited the company's diversified portfolio and category leadership, as well as pipeline initiatives, as reasons to be positioned attractively in 2025.

RBC Capital also said the company's 2025 guidance was "prudent and achievable," but one that it is positioned to beat and raise from.

The firm has an outperform rating on the stock with a price target of $105.

Price: 98.76, Change: +0.59, Percent Change: +0.60